A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects
Status:
Active, not recruiting
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
A single center, randomized, doubled-blind, placebo-control and single ascending dose study
to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of LY-CovMab
Injection in Chinese healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Luye Pharma Group Ltd.
Collaborators:
Shandong Boan Biotechnology Co Ltd Shandong Boan Biotechnology Co., Ltd